R vs. Phoenix & SAS? [🇷 for BE/BA]

posted by yjlee168 Homepage – Kaohsiung, Taiwan, 2015-04-20 21:36 (3291 d 07:17 ago) – Posting: # 14719
Views: 22,979

Dear Helmut,

❝ What would we need in bear?


Wow! thank you so much. But that's too much. It must be a typo. May I suggest as "what we can do with R?" There are lots of R users/gurus in this Forum.

❝ For the FDA that would be a mixed-effects model as given in the 2001 guidance and the pro­ge­sterone guidance.


I like this.

❝ For the EMA we would need an “all effects fixed” model (Method A of the Q&A).


One stupid question :-D: if EMA needs an "all effects fixed" model, why do we use a mixed model to do analysis? I don't remember lme() right now, but lmer() must have at least a random variable. I tried lmer() last night and was pretty sure about that. Does EMA imply that we should use lm() to analyze replicate crossover dataset?:confused:

FDA – RSABE: Again the progesterone guidance.

❝ EMA – ABEL: The Q&A, Methods A & B. Crippled model to get CVwR...


❝ I would say, that’s the target.


You should try to get funded from EMA or FDA for these projects. These are really great projects, indeed.

All the best,
-- Yung-jin Lee
bear v2.9.1:- created by Hsin-ya Lee & Yung-jin Lee
Kaohsiung, Taiwan https://www.pkpd168.com/bear
Download link (updated) -> here

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,657 registered users;
61 visitors (0 registered, 61 guests [including 9 identified bots]).
Forum time: 04:54 CEST (Europe/Vienna)

So far as I can remember,
there is not one word in the Gospels
in praise of intelligence.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5